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BACKGROUND: Increasing numbers of emergency
medical service agencies and hospitals are developing
the capability to administer blood products to patients
with hemorrhagic shock. Cold-stored whole blood
(WB) is the only single product available to prehospital
providers who aim to deliver a balanced resuscitation
strategy. However, there are no data on the safety and
in vitro characteristics of prehospital stored WB. This
study aimed to describe the effects on in vitro quality of
storing WB at remote helicopter bases in thermal
insulating containers.
STUDY DESIGN AND METHODS: We conducted a
two-armed single-center study. Twenty units (test) were
stored in airtight thermal insulating containers, and
20 units (controls) were stored according to routine
procedures in the Haukeland University Hospital Blood
Bank. Storage conditions were continuously monitored
during emergency medical services missions and
throughout remote and blood bank storage. Hematologic
and metabolic variables, viscoelastic properties, and
platelet (PLT) aggregation were measured on Days 1, 8,
14, and 21.
RESULTS: Storage conditions complied with the EU
guidelines throughout remote and in-hospital storage for
21 days. There were no significant differences in PLT
aggregation, viscoelastic properties, and hematology
variables between the two groups. Minor significantly
lower pH, glucose, and base excess and higher lactate
were observed after storage in airtight containers.
CONCLUSION: Forward cold storage of WB is safe and
complies with EU standards. No difference is observed
in hemostatic properties. Minor differences in metabolic
variables may be related to the anaerobic conditions
within the thermal box.
ABBREVIATIONS: aPTT = activated partial thromboplastin time;
BE = base excess; CWB = cold whole blood; DCR = damage control
resuscitation; LTA = light transmission aggregometry; MA =
maximum achieved clot strength; HEMS = helicopter emergency
medical services; PRP = platelet-rich plasma; TRAP = thrombin
receptor-activating peptide; WB = whole blood.
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D
uring the past two decades there has been a
paradigm shift in resuscitation strategies for
major hemorrhage and hemorrhagic shock.1–3
Damage control resuscitation (DCR) strategies
now favor the early transfusion of blood components con-
taining red blood cells (RBCs), platelets (PLTs), and plasma,
contradicting the previous policies favoring the use of clear
fluids. Although definitive evidence concerning transfusion
ratios is lacking, there is a strong trend to aim for physiologic
ratios of blood components in the initial phase of resuscita-
tion. Simultaneously, there is a clear vision that the pre-
hospital phase should be as short as possible even if blood
components are available at an early stage.4–6 Balanced blood
product replacement aims at addressing both shock and
coagulopathy, which underscores the rationale for starting
this approach in the prehospital phase of care. A growing
number of prehospital emergency services in Europe and the
United States have implemented this strategy.7 Although
DCR principles address trauma, early prehospital transfusion
of blood products may also benefit patients who suffer from
hemorrhagic shock due to medical conditions.8 It is also
common for helicopter emergency medical services (HEMS)
to respond to rural clinics and hospitals with limited transfu-
sion capabilities for stabilization and subsequent transport of
bleeding patients. Prehospital transfusion programs may be
of value in these circumstances as well.
Owing to the logistics and limitations associated with
transfusion in the prehospital arena, DCR based on compo-
nent therapy may not be feasible. At present, cold-stored
RBCs and lyophilized plasma are the components most
widely used in the prehospital environment.9 Hence, the
PLT supply is the weak link to achieve what may be consid-
ered currently a “gold standard” DCR. In most circum-
stances it is logistically impossible to supply room
temperature–stored agitated PLTs for forward resuscitation.
Even if cold-stored PLTs are considered as an alternative,
the component-based strategy suffers from the fact that the
1:1:1 ratio yields a dilute mixture because of the RBC addi-
tive solutions.10 Second, it is a great logistic challenge for
the prehospital provider to deliver three different products
simultaneously in a time-sensitive emergency. Recent expe-
rience from the war theaters in Iraq and Afghanistan suggest
that whole blood (WB) resuscitation for trauma victims may
be a viable option in this context.11–15
At present in excess of 30 HEMS in the United States
and Norway carry cold-stored low-titer group O WB to
patients. Further, several military units have implemented
WB in war theaters over the past 6 years.13,16,17
The storage conditions for cold WB (CWB) in the pre-
hospital environment differ from in-hospital CWB storage.
Prehospital CWB is usually stored in closed isothermal con-
tainers. Impaired gas-exchange conditions raise concerns
about the potential reduction in hemostatic function due to
impaired PLT function in the product.
The problem with adhering to storage standards may
be a reason why some emergency medical services no lon-
ger carry blood. The lack of data on prehospital storage con-
ditions and data on the hemostatic function of prehospital
stored WB is the rationale for conducting this study.18
In our study we wanted to assess how forward cold
storage of WB in a civilian emergency helicopter service
would affect the product quality. Our primary objective was
to evaluate if the storage conditions support blood that
complies with EU standards for up to 21 days of storage.19
The secondary objective was to assess product in vitro qual-
ity and hemostatic function of WB during storage for up to
21 days in an approved airtight thermal insulating storage
container.
MATERIALS AND METHODS
Study design and ethics
This is a prospective single-center, two-armed observational
study of forward storage of WB in airtight thermal insulating
storage containers. The study was conducted at the Depart-
ment of Immunology and Transfusion Medicine, Haukeland
University Hospital (Bergen, Norway), and at the Norwegian
Air Ambulance HEMS base Grønneviksøren (Bergen,
Norway), a location 2 km from Haukeland University Hospi-
tal, from May to October 2017. According to routine proce-
dures for the Bergen HEMS prehospital blood program, WB
units in the test group (HEMS group) were stored continu-
ously in an airtight approved container at the HEMS base
for 1 week before being returned to the blood bank for con-
tinuous total storage of 21 days in the thermal container.
The control group units were stored according to routine
procedures without agitation in a temperature-controlled
refrigerator at 4  2oC in the blood bank the entire study
period. Sampling from the test units was performed imme-
diately before and after transfer to the base. The test units
were included in the study from the regular inventory at the
HEMS base if not used at the HEMS base within 7 days of
storage. There were no patient interventions. The study was
approved by the regional ethics committee (REK ID
2017/157). Informed written consent was obtained from all
donors of WB.
Bergen HEMS
The emergency helicopter service in Bergen, Norway,
responds to both medical and trauma cases in a 60:40 ratio
24 hr/day 365 days/year. The HEMS is staffed with an expe-
rienced prehospital anesthesiologist, a HEMS rescue para-
medic, and a pilot. Emergency response is carried out by
helicopter or by a rapid response car. Bergen HEMS
implemented routinely cold-stored, leukoreduced low-titer
group O WB for remote hemostatic resuscitation in
December 2015. Also, lyophilized plasma is available in the
service.
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Collection and preparation of WB units
Whole blood was collected from regular blood donors using
the 450-mL WB-SP CPD collection set (BB*LGQ456E6, Ter-
umo BCT). The WB units were rested for 2 hours followed
by a gravitational filtration through the inline PLT-sparing,
leukoreducing filter, allowing for a PLT content of more
than 90% of the unit before filtration. The residual white
blood cell (WBC) concentration was less than 1 × 106/unit,
in line with requirements for cellular blood components. To
minimize risk of hemolytic transfusion reactions, all blood
donors had blood group O. The titers of IgM anti-A and
anti-B were below 256 and all units were correspondingly
labeled “low titer.” Two CWB units were dispatched to the
HEMS service each week.
Cold chain maintenance and forward monitoring
The test group WB units (n = 20) were transferred to an
approved primed portable thermal container (Credo
Duracube HD with Golden Hour inner container, Pelican
BioThermal) together with a data logger that recorded
ambient temperature, three-axis acceleration, humidity,
light, and barometric pressure (MSR 145 mini datalogger,
MSR Electronics GMBH). According to local routines, the
container was then placed in a regular refrigerator at the
HEMS base. The units were carried on missions in the con-
tainer for 7 days before returned to the Department of
Immunology and Transfusion Medicine at Haukeland
University Hospital and then stored in the same container
for an additional 14 days up to a total of 21 days. The con-
tainer was only brought on HEMS missions involving calls
to patients with potential bleeding. HEMS crew members
recorded the duration of the mission and how long the ther-
mal box was outside the refrigerator. These records were
compared to the data logger recordings inside the box. Con-
trol group WB units (n = 20) were stored without agitation
in a conventional approved, monitored refrigerator (2-6°C)
in the blood bank according to routine.
Laboratory investigations
Samples were collected on Days 1, 8, 14, and 21 by sterile
transfer of approximately 25 mL to a transfer bag (Teruflex,
BB*T015CM, Terumo BCT), which was then used to further
aliquot to the appropriate sample tubes.
Leukoreduction status was verified by counting
residual WBCs using the WBC counting kit and flow
cytometer (BD LeucoCount and a FACSCanto II, respec-
tively (BD Biosciences;). Hematologic variables (hemoglobin
[Hb], hematocrit [Hct], RBC count, PLT count, and mean
PLT volume) were quantified with a hematology analyzer
(Cell-Dyn Sapphire, Abbott Diagnostics). To evaluate hemo-
lysis, Hb in plasma was measured on a plasma/low Hb
photometer (HemoCue, HemoCue AB) and percent hemo-
lysis wad calculated as ((plasma-Hb/10) × (100 − Hct))/Hb.
Blood gas variables (pH, pO2, pCO2, and base excess
[BE]) were analyzed on a blood gas analyzer (ABL825
FLEX, Radiometer Medical ApS). Sodium and potassium,
glucose, and lactate levels were measured on a chemis-
try analyzer (Cobas 8000, ISE/c702, Roche Diagnos-
tics GmbH).
The effects of storage on coagulation were studied
by measuring activated partial thromboplastin time
(aPTT), prothrombin time/international normalized ratio
(INR), Factor (F)VIII and fibrinogen using a hemostasis
analyzer (STA-R Evolution/STA-R Max; STA-Liquid
Fib/STA-Fibrinogen 5, STA-Deficient VIII, STA-SPA+,
STA-PTT Automate 5, STA-CaCl2 and STA-Unicalibrator,
Stago S.A.S.).
The hemostatic function was evaluated by kaolin-
initiated thromboelastography on a thromboelastograph
(TEG 5000, Haemonetics Corporation) and quantified as
time to start of clot formation, clot formation speed (angle),
and maximum achieved clot strength (MA).
To quantify PLT aggregation, we performed multiplate
impedance aggregometry (Roche Diagnostics GmbH) with
6.5 μmol/L adenosine diphosphate (ADP), and light trans-
mission aggregometry (LTA; Chrono-log Model
700, Chrono-log Corporation) with 10 μmol/L ADP and
30 μmol/L thrombin receptor-activating peptide 6 (TRAP-6,
Roche Diagnostics GmbH).
Samples for impedance aggregometry were analyzed
using the manufacturerʼs procedure for citrated samples,
including partial recalcification with 3 mmol/L CaCl2. PLT-
rich plasma (PRP) for LTA was prepared by 200 × g centrifu-
gation for 10 minutes. The remaining material was further
centrifuged at 1500 × g for 15 minutes to yield PLT-poor
plasma. PLT count in PRP was verified to be in the
150 × 109 to 600 × 109/L range.20 PRP and PLT-poor plasma
was visually inspected for hemolysis and lipemia and incu-
bated at 37°C for 3 minutes before performing LTA at 37°C
with 1000 RPM stirring. Samples were run in two parallels,
and the mean was reported.
Platelet activation and adhesion were also investigated in
8 control units and 6 HEMS units by use of flow cytometry.
Samples were stimulated with 2,8 μL ADPtest and 1,7 μL
TRAPtest. A premade mix of monoclonal mouse anti-human
antibodies were thereafter added without further incubation
(BD Bioscience) with PerCP CD61 (Clone EUU-PL 7 F12, Cat.
No. 347408), APC CD42b (Cat. No. 551061), and PE CD62P
(Cat. No. 561921). Thirty minutes of incubation in the dark at
room temperature was followed by a RBC lysing step where
we added 465 μL of lysis buffer (Dako EasyLyse, Ref.
No. S2364, Agilent). After 2 mL of flow cytometry sheath fluid
(FACSFlow, Cat. No. 342003, BD Biosciences) was added, the
samples were run on a flow cytometer using its software
(BD FACSCanto II and FACSDiva, Version 8.0.1, respectively,
BD Biosciences). We gated the PLTs using forward scatter
height versus area to avoid doublets and side scatter versus for-
ward scatter to narrow the gating. The same gating was used
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on all samples, regardless of age. Results reported as age of
percent parent of CD61-positive cells for the activation
markers.
Statistical analysis
The effect of forward storage in an airtight container at the
HEMS base on each of the outcome variables was investi-
gated using a linear mixed-effect model with storage time,
study group, and their interaction as predictors. In this
model, we used simple contrasts to investigate whether the
outcome variables changed from Day 1 to 8, Day 1 to
14, and Day 1 to 21. Additionally, we used the interaction
between storage time and study group to describe whether
this level of change was different between the blood stored
at the blood bank and at the HEMS base. The p value
reported in the text and figures are for this interaction.
Potential differences in age and sex distribution between
the two groups were examined using independent-sample
t tests. A p value of less than 0.05 was considered signifi-
cant. Results were presented as mean (95% confidence
interval [CI]). All analyses were performed with computer
software (R version 3.6.0 with the NLME package version
3.1-140, The R Foundation for Statistical Computing).
We found no previous studies that could be used for
sample size calculation. With the general assumption of
normality for outcome measures enabling the use of a two-
sided t-test, setting the mean to 1 and a standard deviation
to 0.5 with a significance level of 0.05 and a power of 0.8,
we found that we needed a minimum of 17 individual units
in each group. Based on this we chose to include 20 WB
units in each study group.
RESULTS
Quality requirements
A total of 40 CWB units were monitored and tested, 20 in
the HEMS group and 20 in the control group. During stor-
age at the HEMS base, there were no recorded breaches of
temperature limits (1-10°C). Table 1 show the number of
HEMS missions in which CWB were carried and the total
duration of storage outside of the refrigerator. The blood
was carried on a mean (95% CI) number of 4.1 (2.86-5.34)
missions. The mean (95% CI) duration of the missions was
339 (209-469) minutes.
All units in the study complied with the requirements
set forth in the “Guide to the Preparation, Use and Quality
Assurance of Blood Components.”19 The hemolysis at the
end of storage was below the EU requirement of 0.8% of the
RBC mass in all units throughout storage in both groups. The
Hb level was above the EU requirements of 43 g/unit in all
observed units until the end of storage (Table S1, available as
supporting information in the online version of this paper).
Changes during 21-day storage
Hematology
There was no significant difference in change during storage
regarding PLT count, mean PLT volume, or number of RBCs
between the two groups (Fig. 1A, Table S1). We found a sta-
tistically significant difference in the change of Hb levels
from Day 1 to Day 21 between the two groups (p < 0.05;
Fig. 1B).
Clinical chemistry
We found no significant difference in change in potassium
between the two groups during 21 days of storage (Fig. 1C).
Metabolism
When investigating how the metabolic markers changed in
the two groups, we found that the glucose concentration
declined more in the HEMS group on Days 8, 14, and
21 (p < 0.05) compared to the control group (Fig. 1D). The
same was evident in regard to pH and BE (Fig. 1E and
Table S1). Conversely, we found that the lactate increased
significantly in the HEMS group compared to the control
group (Fig. 1F).
Hemostatic properties
There was no significant difference in change in fibrinogen,
international normalized ratio and FVIII levels (Figs. 1G and
1H and Table S1). However, we found a reduction in aPTT
on Day 21 in the test group (Fig. 1I). When investigating the
change in hemostatic capacity by thromboelastography, we
found no difference in change during storage regarding time
to start of clot formation and K between the two groups
(Fig. 1J and Table S1). However, we found that the TEG
angle declined less in the HEMS group compared to the
control group on Days 8, 14, and 21 (p < 0.05; Fig. 1K). This
was also observed in regard to TEG MA, where the TEG MA
declined less in the HEMS group (Fig. 1L). As discussed
later, we also observed significant differences between the
two groups at baseline.
When investigating the PLT aggregation capacity by the
use of the multiplate analyzer with ADP test, we found no
TABLE 1. Number and duration of HEMS missions
where WB units were carried*
WB unit Number of missions Mission duration (min)
1 & 2 3 120
3 & 4 6 600
5 & 6 3 180
7 & 8 6 360
9 & 10 6 420
11 & 12 2 180
13 & 14 4 300
15 & 16 3 360
17 & 18 6 660
19 & 20 2 210
* There were no recorded temperature breaches.
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significant difference during storage between the two groups
(Fig. 1M). There were also no differences between the two
groups when utilizing LTA to assess maximum aggregation
with TRAP and ADP as stimulants (Figs. 1N and 1O). The
spontaneous aggregation was comparable in the two groups
(Table S1). Finally, in regard to PLT function, we found no
significant difference between the two groups when investi-
gating ADP- and TRAP-stimulated expression of CD62P and
CD42b by flow cytometry (Table S1).
Additional findings
We found a statistically significant difference in pH, BE,
and TEG MA on Day 1, indicating that there was a differ-
ence between the two groups at baseline in these variables.
There were no significant differences between the groups
in the distribution of donor ages (HEMS 36.2 [30.3-42.1]
versus control 42.6 [36.1-49.1]; p = 0.134) and sex (HEMS
15 male, five female vs. control nine male, 11 female;
p = 0.053).
DISCUSSION
This study evaluated changes in hematology, clinical chem-
istry, metabolism, and hemostatic variables of CWB stored
in an airtight thermal box forward at a HEMS base, for up to
21 days, compared to changes of CWB stored according to
routine practice in the blood bank. All CWB units complied
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Fig. 1. Mean and 95% CIs of the variables during 21 days of storage. ( ) Control group; ( ) HEMS group. A linear mixed-effects
model with storage time, study group, and their interaction as predictors was fitted. The p value shown represents the interaction
between storage time and study group and signifies whether there was a significant difference between the two groups in how the
variable changed from Day 1 to 8, Day 1 to 14, and Day 1 to 21. [Color figure can be viewed at wileyonlinelibrary.com]
1548 TRANSFUSION Volume 60, July 2020
BJERKVIG ET AL.
with the requirements set forth in the “Guide to the Prepa-
ration, Use and Quality Assurance of Blood Components”
throughout storage for 21 days, regardless of storage condi-
tions. The hemolysis grade was below 0.8% of the total RBC
mass, and that the Hb content was above 43 g/unit.19
The storage of CWB at the HEMS base revealed no
safety concerns concerning temperature limits (1-10°C).
This is important as increased temperature may compro-
mise the product quality.21–23 Thus, the crew must be vigi-
lant in monitoring the operability of the refrigerator and to
ensure that there has not been breach of temperature limits
before administering the blood in the field. Temperature
monitoring is an essential part of quality control in transfu-
sion medicine. One of the main disadvantages of the pre-
sent storage container is that the crew must open the box to
read the logger. Future designs should consider providing
an external temperature reading on the thermal box to
improve safety.24
The number of missions varied from two to six, and
the total duration of missions varied from 120 to
660 minutes for the blood units in the HEMS group. In
addition to changes in temperature, the blood properties
could potentially be influenced by changes in pressure and
vibration during missions. Due to the low number in each
group, we were not able to adjust for differences in the
amount and duration of missions in the results. However,
if these factors were substantial, we would expect the vari-
ance of the results in the HEMS group to be generally
larger than that in the control group (Table S1). Generally,
for all our outcome measures small CIs were observed in
both groups.
We found a significant difference in how the Hb levels
had changed in the two groups at 21 days of storage. How-
ever, the difference between the two groups is without clini-
cal significance as the difference in change of Hb
concentration between the two groups was only 0.05 g/dL.
Prehospital CWB is stored in an airtight thermal box
and placed inside a conventional refrigerator at the HEMS
base. The changes in metabolic variables during storage
and comparison between the two groups suggest that there
are minor alterations in gas exchange conditions for CWB
stored in airtight thermal insulated storage containers. We
observed slightly higher lactate levels and lower BE and
pH levels in CWB stored forward. The clinical impact of
these values is uncertain and probably without impor-
tance. There was a significant difference in how aPTT had
changed at 21 days, with less increase in the HEMS group
on Day 21. The difference was minimal and for the benefit
of the HEMS group, however, probably without clinical
significance.
Viscoelastic hemostatic capacity as measured by TEG
was present in both groups for the entire 21-day storage
period. As mentioned, we found that the TEG angle had
declined less in the HEMS group. The TEG angle measures
the speed at which fibrin builds up and cross-links. Hence,
the angle assesses the rate of clot formation. This process is
propagated by thrombin formation and is dependent on
PLTs and fibrinogen. We did not find that there was a signif-
icant difference in these measurements on Day 1, nor any
difference in how these variables changed. Based on this, it
seems unlikely that the difference in the TEG angle can be
explained by PLT and fibrinogen effects. Further, there was
also a significant difference in the TEG MA evolution during
storage. Again, it declined less in the HEMS group. The TEG
MA represents in simple terms the ultimate strength of the
fibrin clot, dependent on PLT function and fibrin levels. We
did not find significant differences when evaluating PLT
count and function using LTA and multiplate or flow
cytometry.
When it comes to the hemostatic properties of CWB
in general, these results show that viscoelastic hemostatic
properties are to a great extent maintained for up to
21 days. The final MA in both groups was approximately
50, whereas the plasma fibrin contribution to clot strength
alone typically yields an MA of 10.25 This indicates that
the PLTs in CWB retain considerable ability to catalyze
clot formation and contraction throughout storage dura-
tion. The PLT function as measured by PLT aggregation
and agonist-induced glycoprotein expression was pre-
served for at least up to 8 days of storage, after this we
observed a decline in response. This is consistent with
previous studies.26–28
We found significant differences in pH, BE, and TEG
MA, between the two groups on Day 1. We performed sec-
ondary analysis to see if the differences were related to
the distributions of sex and age between the groups but
did not find a statistical relationship. However, examining
the data, although not significant, the mean PLT count
was 175 in the control group versus 155 in the HEMS
group. The TEG MA is affected by PLT count, and this
may explain this finding. Regarding pH and BE, although
there were significant differences at baseline, the actual
values are without clinical significance (mean pH 6.97 in
control group vs. 6.99 in HEMS group). Further, these
findings should not interfere with secondary objective
results as the statistical design takes into account differ-
ences at baseline.
We conclude that storage of CWB in thermal con-
tainers in a prehospital emergency service is feasible. The
logistics and maintenance of the thermal conditions are
easy and safe. The product quality is within EU regulations
for up to 21 days of storage. The hemostatic properties of
CWB stored prehospital are similar to those of CWB stored
in the blood bank. The PLT function in CWB deteriorates
after 8 days of storage but is still clinically useful for up to
21 days. These findings support the practice of extending
storage in resource-poor environments and thus reducing
waste.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article.
Table S1. Mean and 95% confidence intervals for all mea-
sured variables. A linear mixed effect model with storage
time, study group and their interaction as predictors was
fitted. For time, simple contrasts were used. pDay signifies
whether there was a statistically significant change from
Day 1 to the specified storage day. pInteraction signifies
whether this change was statistically different between the
two study groups. The pInteraction given for Day 1 indicates
whether the baseline measurement was significantly differ-
ent in the two groups.
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